Germany
· Delayed Price · Currency is EUR BRM Statistics
Total Valuation
Bristol-Myers Squibb Company has a market cap or net worth of EUR 102.87 billion. The enterprise value is 142.81 billion.
| Market Cap | 102.87B |
| Enterprise Value | 142.81B |
Important Dates
The last earnings date was Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | Oct 4, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.52% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.02B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.83, with an EV/FCF ratio of 11.54.
| EV / Earnings | -21.95 |
| EV / Sales | 3.25 |
| EV / EBITDA | 7.83 |
| EV / EBIT | 17.12 |
| EV / FCF | 11.54 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 2.99.
| Current Ratio | 1.24 |
| Quick Ratio | 1.02 |
| Debt / Equity | 2.99 |
| Debt / EBITDA | 2.62 |
| Debt / FCF | 3.73 |
| Interest Coverage | 5.09 |
Financial Efficiency
Return on equity (ROE) is -31.33% and return on invested capital (ROIC) is 8.20%.
| Return on Equity (ROE) | -31.33% |
| Return on Assets (ROA) | 6.07% |
| Return on Capital (ROIC) | 8.20% |
| Revenue Per Employee | 1.25M |
| Profits Per Employee | -190,836 |
| Employee Count | 34,100 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.38% in the last 52 weeks. The beta is 0.46, so Bristol-Myers Squibb Company's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +2.38% |
| 50-Day Moving Average | 47.15 |
| 200-Day Moving Average | 44.11 |
| Relative Strength Index (RSI) | 61.50 |
| Average Volume (20 Days) | 2,225 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.09 |
Income Statement
In the last 12 months, Bristol-Myers Squibb Company had revenue of EUR 42.53 billion and -6.51 billion in losses. Loss per share was -3.21.
| Revenue | 42.53B |
| Gross Profit | 32.27B |
| Operating Income | 8.06B |
| Pretax Income | -6.17B |
| Net Income | -6.51B |
| EBITDA | 17.18B |
| EBIT | 8.06B |
| Loss Per Share | -3.21 |
Balance Sheet
The company has 7.26 billion in cash and 46.12 billion in debt, giving a net cash position of -38.57 billion.
| Cash & Cash Equivalents | 7.26B |
| Total Debt | 46.12B |
| Net Cash | -38.57B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.42B |
| Book Value Per Share | 7.58 |
| Working Capital | 4.87B |
Cash Flow
In the last 12 months, operating cash flow was 13.45 billion and capital expenditures -1.08 billion, giving a free cash flow of 12.38 billion.
| Operating Cash Flow | 13.45B |
| Capital Expenditures | -1.08B |
| Free Cash Flow | 12.38B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.87%, with operating and profit margins of 18.95% and -15.30%.
| Gross Margin | 75.87% |
| Operating Margin | 18.95% |
| Pretax Margin | -14.50% |
| Profit Margin | -15.30% |
| EBITDA Margin | 40.40% |
| EBIT Margin | 18.95% |
| FCF Margin | 29.10% |
Dividends & Yields
Bristol-Myers Squibb Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 3.66% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 3.52% |
| Shareholder Yield | 3.52% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bristol-Myers Squibb Company has an Altman Z-Score of 1.91. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.91 |
| Piotroski F-Score | n/a |